L-Prolinamide, N-(methylsulfonyl)-D-phenylalanyl-N-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]- manufacturers
- BMS-189664
-
- $1820.00
-
2026-04-20
- CAS:162166-80-5
- Purity:
- Supply Ability: 10g
|
| | L-Prolinamide, N-(methylsulfonyl)-D-phenylalanyl-N-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]- Basic information |
| | L-Prolinamide, N-(methylsulfonyl)-D-phenylalanyl-N-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]- Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | pka | 9.49±0.40(Predicted) |
| | L-Prolinamide, N-(methylsulfonyl)-D-phenylalanyl-N-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]- Usage And Synthesis |
| Uses | BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research[1]. | | in vivo | BMS-189664 is efficacious at protecting mice from thrombin-induced lethality[1].
BMS-189664 (0.2 mg/kg, iv) inhibits arterial thrombosis in cynomolgus monkey models[1].
BMS-189664 (infused at 9, 25, and 100 mg/kg/min for 1 h to achieve 0.5, 2, and 6 mg/kg) inhibits venous thrombosis in cynomolgus monkey models[1].
The oral bioavailability of BMS-189664 based on the dose-normalized AUCs after oral and iv dosing was 15 and 17% in dogs and monkeys, respectively[1].
| | References | [1] Das J, et al. Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Bioorg Med Chem Lett. 2002 Jan 7;12(1):45-9. DOI:10.1016/s0960-894x(01)00667-9 |
| | L-Prolinamide, N-(methylsulfonyl)-D-phenylalanyl-N-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]- Preparation Products And Raw materials |
|